Healthcare providers don’t have time to research every drug on the market. Viatris found that doctors are more likely to be interested in a drug if they hear about it from a colleague or see it promoted on the social network for doctors, Doximity.

For YUPELRI, we came up with two tactics: an article and a video to be published and shared on Doximity. To drive interest and engagement, both tactics covered the efficacy of YUPELRI and established it as the first and only Long-Acting Muscarinic Antagonist (LAMA) to improve lung function for 24 hours.